BRPI0608327A2 - potenciador para terapia de radiação compreendendo derivado de piridina como ingrediente ativo - Google Patents
potenciador para terapia de radiação compreendendo derivado de piridina como ingrediente ativoInfo
- Publication number
- BRPI0608327A2 BRPI0608327A2 BRPI0608327-7A BRPI0608327A BRPI0608327A2 BR PI0608327 A2 BRPI0608327 A2 BR PI0608327A2 BR PI0608327 A BRPI0608327 A BR PI0608327A BR PI0608327 A2 BRPI0608327 A2 BR PI0608327A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- radiation therapy
- active ingredient
- pyridine derivative
- carbon atoms
- Prior art date
Links
- 238000001959 radiotherapy Methods 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 239000003623 enhancer Substances 0.000 title abstract 3
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
POTENCIADOR PARA TERAPIA DE RADIAçãO COMPREENDENDO DERIVADO DE PIRIDINA COMO INGREDIENTE ATIVO. Descrito é um potenciador para terapia de radiação que pode ser empregado em combinação com terapia de radiação de câncer para aumentar a dose de radiação e pode também reduzir os efeitos colaterais adversos da terapia de radiação. Um potenciador para terapia de radiação compreendendo, como o ingrediente ativo, um derivado de piridina representado pela formula geral (1) onde R^ 1^, R^ 2^, e R^ 4^ independentemente representam um átomo de hidrogênio, grupo hidróxi, ou grupo hidróxi protegido, desde que todos R^ 1^, R^ 2^ e R^ 4^ não sejam um átomo de hidrogênio; e R^ 3^ representa um átomo de halogênio, grupo amino, grupo carboxila, grupo carbamoila, grupo ciano, grupo nitro, grupo alquila tendo 1 a 6 átomos de carbono, grupo alquenila tendo 2 a 6 átomos de carbono, ou grupo carbonila contendo um grupo alcóxi tendo 1 a 6 átomos de carbono.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005105938 | 2005-04-01 | ||
| JP2005219119 | 2005-07-28 | ||
| PCT/JP2006/306961 WO2006106984A1 (ja) | 2005-04-01 | 2006-03-31 | ピリジン誘導体を有効成分とする放射線治療増強剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0608327A2 true BRPI0608327A2 (pt) | 2009-12-29 |
Family
ID=37073534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0608327-7A BRPI0608327A2 (pt) | 2005-04-01 | 2006-03-31 | potenciador para terapia de radiação compreendendo derivado de piridina como ingrediente ativo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090137640A1 (pt) |
| EP (1) | EP1864974B1 (pt) |
| JP (1) | JP5103170B2 (pt) |
| KR (1) | KR101135789B1 (pt) |
| AU (1) | AU2006231809B2 (pt) |
| BR (1) | BRPI0608327A2 (pt) |
| CA (1) | CA2603810C (pt) |
| NZ (1) | NZ562048A (pt) |
| RU (1) | RU2415670C2 (pt) |
| TW (1) | TWI371447B (pt) |
| WO (1) | WO2006106984A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006106984A1 (ja) * | 2005-04-01 | 2006-10-12 | Taiho Pharmaceutical Co., Ltd. | ピリジン誘導体を有効成分とする放射線治療増強剤 |
| EP2431032A4 (en) * | 2009-05-12 | 2012-11-07 | Taiho Pharmaceutical Co Ltd | ANTICROBIAL AGENTS WITH A TEGAFUR GIMERACIL OTERACIL CALIUM COMBINATION AND OXALIPLATIN |
| MX2015008010A (es) | 2012-12-20 | 2016-04-26 | qing-bin Lu | Compuestos radiosensabilizadores para usarse en combinacion con radiacion. |
| BR102013022567B1 (pt) * | 2013-09-03 | 2021-09-21 | Uniao Brasileira De Educacão E Assistência | Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana |
| WO2021256427A1 (ja) * | 2020-06-15 | 2021-12-23 | 株式会社Kortuc | 抗がん療法の増感剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6122016A (ja) * | 1984-07-10 | 1986-01-30 | Adeka Argus Chem Co Ltd | 放射線増感剤 |
| JPS61109719A (ja) * | 1984-10-31 | 1986-05-28 | Otsuka Pharmaceut Co Ltd | 抗腫瘍活性増強剤 |
| DE3585869D1 (de) * | 1984-10-30 | 1992-05-21 | Otsuka Pharma Co Ltd | Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung. |
| JP2531952B2 (ja) * | 1987-04-06 | 1996-09-04 | 大塚製薬株式会社 | フオスホリラ−ゼ阻害剤 |
| DE60235088D1 (de) * | 2001-07-05 | 2010-03-04 | Taiho Pharmaceutical Co Ltd | Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel |
| US9611227B2 (en) * | 2003-03-14 | 2017-04-04 | Taiho Pharmaceutical Co., Ltd. | Antitumor effect potentiator and antitumor agent |
| WO2006106984A1 (ja) * | 2005-04-01 | 2006-10-12 | Taiho Pharmaceutical Co., Ltd. | ピリジン誘導体を有効成分とする放射線治療増強剤 |
| JP4956423B2 (ja) * | 2005-04-01 | 2012-06-20 | 大鵬薬品工業株式会社 | 放射線治療増強剤 |
-
2006
- 2006-03-31 WO PCT/JP2006/306961 patent/WO2006106984A1/ja not_active Ceased
- 2006-03-31 NZ NZ562048A patent/NZ562048A/en not_active IP Right Cessation
- 2006-03-31 CA CA2603810A patent/CA2603810C/en not_active Expired - Fee Related
- 2006-03-31 EP EP06730909.6A patent/EP1864974B1/en not_active Expired - Lifetime
- 2006-03-31 AU AU2006231809A patent/AU2006231809B2/en not_active Ceased
- 2006-03-31 JP JP2007511214A patent/JP5103170B2/ja not_active Expired - Fee Related
- 2006-03-31 KR KR1020077025043A patent/KR101135789B1/ko not_active Expired - Fee Related
- 2006-03-31 TW TW095111531A patent/TWI371447B/zh not_active IP Right Cessation
- 2006-03-31 RU RU2007140384/15A patent/RU2415670C2/ru active
- 2006-03-31 BR BRPI0608327-7A patent/BRPI0608327A2/pt not_active IP Right Cessation
- 2006-03-31 US US11/910,150 patent/US20090137640A1/en not_active Abandoned
-
2010
- 2010-12-27 US US12/978,743 patent/US8569324B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI371447B (en) | 2012-09-01 |
| US8569324B2 (en) | 2013-10-29 |
| TW200714588A (en) | 2007-04-16 |
| RU2415670C2 (ru) | 2011-04-10 |
| HK1118807A1 (en) | 2009-02-20 |
| RU2007140384A (ru) | 2009-05-10 |
| AU2006231809B2 (en) | 2011-08-25 |
| CA2603810C (en) | 2012-06-26 |
| US20110091016A1 (en) | 2011-04-21 |
| NZ562048A (en) | 2011-12-22 |
| KR20080002900A (ko) | 2008-01-04 |
| EP1864974B1 (en) | 2013-10-09 |
| US20090137640A1 (en) | 2009-05-28 |
| WO2006106984A1 (ja) | 2006-10-12 |
| CA2603810A1 (en) | 2006-10-12 |
| JP5103170B2 (ja) | 2012-12-19 |
| AU2006231809A1 (en) | 2006-10-12 |
| JPWO2006106984A1 (ja) | 2008-09-25 |
| EP1864974A4 (en) | 2009-09-02 |
| EP1864974A1 (en) | 2007-12-12 |
| KR101135789B1 (ko) | 2012-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU747599C (en) | Antitumor agents | |
| CY1107253T1 (el) | Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2h-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου | |
| BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
| DOP2011000203A (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
| BRPI0513184A (pt) | derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia | |
| BR0311806A (pt) | Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso | |
| CR7056A (es) | Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa | |
| CO6341555A2 (es) | Compuestos quimicos 251 | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| GB2433070A (en) | Porphyrin derivatives and their use in photon activation therapy | |
| BR0308784A (pt) | Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| AR050045A1 (es) | Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
| BRPI0412130A (pt) | compostos tetracìclicos como inibidores de c-met | |
| AR047277A1 (es) | Mezclas insecticidas sinergicas | |
| WO2005065074A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| BR0308162A (pt) | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| ATE523513T1 (de) | Pyrazolopyrimidinderivat | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
| Zhang et al. | Synthesis and evaluation of smart drugs with integrated functions for identifying and treating oxidative microenvironments associated with cellular ferroptosis | |
| EP1864974A4 (en) | AMPLIFIER FOR RADIOTHERAPY CONTAINING A PYRIDINE DERIVATIVE AS AN ACTIVE SUBSTANCE | |
| BRPI0613545A2 (pt) | derivados de pirroliltriazina junto com métodos para a sua obtenção e seu uso como agentes de proteção contra radiação uv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 2020-01-28 |